Literature search results

347 articles were found.

The following terms were included: glioblastoma, Glioblastom, 神経膠細胞芽腫

• 2020, Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M
  Management of glioblastoma: State of the art and future directions [basics]
  CA Cancer J Clin 70 (4): 299-312
• 2020, Bokstein F, Blumenthal D, Limon D, Harosh CB, Ram Z, Grossman R
  Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study [med. app.]
  Front Oncol 10: 411
• 2020, Guberina N, Pöttgen C, Kebir S, Lazaridis L, Scharmberg C, Lübcke W, Niessen M, Guberina M, Scheffler B, Jendrossek V, Jabbarli R, Pierscianek D, Sure U, Schmidt T, Oster C, Hau P, Grosu AL, Stuschke M, Glas M, Nour Y, Lüdemann L
  Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial [tech./dosim.]
  Radiat Oncol 15: 83
• 2020, Lang S, Gan LS, McLennan C, Monchi O, Kelly J
  Impact of peritumoral edema during tumor treatment field therapy: a computational modelling study [tech./dosim.]
  IEEE Trans Biomed Eng 67 (12): 3327-3338
• 2020, Halgamuge MN, Skafidas E, Davis D
  [details] A meta-analysis of in vitro exposures to weak radiofrequency radiation exposure from mobile phones (1990-2015) [review]
  Environ Res 184: 109227
• 2020, Kim CY, Paek SH, Nam DH, Chang JH, Hong YK, Kim JH, Kim OL, Kim SH
  Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial [med. app.]
  J Neurooncol 146 (3): 399-406
• 2020, Lok E, San P, Liang O, White V, Wong ET
  Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma [tech./dosim.]
  J Neurooncol 147 (1): 125-133
• 2020, Davis FG, Smith TR, Gittleman HR, Ostrom QT, Kruchko C, Barnholtz-Sloan JS
  Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015 [comment]
  Neuro Oncol 22 (2): 301-302
• 2019, Sprugnoli G, Monti L, Lippa L, Neri F, Mencarelli L, Ruffini G, Salvador R, Oliveri G, Batani B, Momi D, Cerase A, Pascual-Leone A, Rossi A, Rossi S, Santarnecchi E
  Reduction of intratumoral brain perfusion by noninvasive transcranial electrical stimulation [med. app.]
  Sci Adv 5 (8): eaau9309
• 2019, Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, Lee YJ, Cho JM, Kwak SY, Baek JH, Jeong YK, Song JY, Yoon M, Hwang SG
  Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells [med./bio.]
  Oncogene 38 (39): 6630-6646
• 2019, Soni VS, Yanagihara TK
  Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging [basics]
  Cancer Imaging 19 (1): 76
• 2019, Gentilal N, Salvador R, Miranda PC
  Temperature control in TTFields therapy of GBM: impact on the duty cycle and tissue temperature [tech./dosim.]
  Phys Med Biol 64 (22): 225008
• 2019, Korshøj AR, Lukacova S, Mikic N, Cortnum SOS, Lassen-Ramshad Y, Guldberg TL, Severinsen KE, Thielscher A, Poulsen FR, Sørensen JCH, Oettingen GBV
  [Tumor treating fields in cancer treatment in Denmark] [foreign-language]
  Ugeskr Laeger 181 (20A): V07180481
• 2019, Thomas AA, Rauschkolb PK
  Tumor treating fields for glioblastoma: should it or will it ever be adopted? [basics]
  Curr Opin Neurol 32 (6): 857-863
• 2019, Toms SA, Kim CY, Nicholas G, Ram Z
  Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial [med. app.]
  J Neurooncol 141 (2): 467-473
• 2019
  [Tumour-treating fields in addition to current standard therapy for glioblastoma as first-line treatment] [info]
  Institute for Quality and Efficiency in Health Care (IQWiG), Rapid Report N18-02 Version 1.1, IQWiG-Berichte – Nr. 772: 1-62
• 2019, Wang Y, Pandey M, Ballo MT
  [details] Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies [review]
  Oncologist 24 (12): e1426-e1436
• 2019, Cobbs C, McClay E, Duic JP, Nabors LB, Morgan DM, Kesari S
  An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US [med. app.]
  CNS Oncol 8 (1): CNS30
• 2019, Murphy M, Dowling A, Thien C, Priest E, Morgan Murray D, Kesari S
  A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia [med. app.]
  CNS Oncol 8 (1): CNS31
• 2019, García-Minguillán López O, Jiménez Valbuena A, Maestú Unturbe C
  Significant Cellular Viability Dependence on Time Exposition at ELF-EMF and RF-EMF In Vitro Studies [med./bio.]
  Int J Environ Res Public Health 16 (12): e2085
• 2019, Ahmadi-Zeidabadi M, Akbarnejad Z, Esmaeeli M, Masoumi-Ardakani Y, Mohammadipoor-Ghasemabad L, Eskandary H
  Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration [med./bio.]
  Electromagn Biol Med 38 (3): 198-209
• 2019, Natukka T, Raitanen J, Haapasalo H, Auvinen A
  Incidence trends of adult malignant brain tumors in Finland, 1990-2016 [epidem.]
  Acta Oncol 58 (7): 990-996
• 2019, Jo Y, Sung J, Jeong H, Hong S, Jeong YK, Kim EH, Yoon M
  Effectiveness of a Fractionated Therapy Scheme in Tumor Treating Fields Therapy [med./bio.]
  Technol Cancer Res Treat 18: 1533033819845008
• 2019, Riley MM, San P, Lok E, Swanson KD, Wong ET
  The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma [med. app.]
  J Vis Exp (146): e58937
• 2019, Lyon JG, Carroll SL, Mokarram N, Bellamkonda RV
  Electrotaxis of Glioblastoma and Medulloblastoma Spheroidal Aggregates [med./bio.]
  Sci Rep 9: 5309
• 2019, Makinistian L, Marková E, Belyaev I
  A high throughput screening system of coils for ELF magnetic fields experiments: proof of concept on the proliferation of cancer cell lines [tech./dosim.]
  BMC Cancer 19: 188
• 2019, Karipidis K, Elwood M, Benke G, Sanagou M, Tjong L, Croft RJ
  Correction: Mobile phone use and incidence of brain tumour histological types, grading or anatomical location: a population-based ecological study [erratum]
  BMJ Open 9 (1): e024489corr1
• 2019, Korshøj AR, Lukacova S, Mikic N, Stigaard Cortnum SO, Lassen-Ramshad Y, Guldberg TL, Severinsen KE, Thielscher A, Poulsen FR, Hedemann Sørensen JC, von Oettingen GB
  [Tumor treating fields in cancer treatment in Denmark] [foreign-language]
  Ugeskr Laeger 181 (5): 2-6
• 2019, Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schüler U, Zips D, Eckert F, Huber SM
  Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells [med./bio.]
  Cancers 11 (1): E110
• 2019, Korshoej AR, Sørensen JCH, von Oettingen G, Poulsen FR, Thielscher A
  Optimization of tumor treating fields using singular value decomposition and minimization of field anisotropy [tech./dosim.]
  Phys Med Biol 64 (4): 04NT03
• 2019, Fiorentini G, Sarti D, Milandri C, Dentico P, Mambrini A, Fiorentini C, Mattioli G, Casadei V, Guadagni S
  Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study [med. app.]
  Integr Cancer Ther 18: 1534735418812691
• 2019, Olsson A, Bouaoun L, Auvinen A, Feychting M, Johansen C, Mathiesen T, Melin B, Lahkola A, Larjavaara S, Villegier AS, Byrnes G, Deltour I, Schüz J
  Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden [epidem.]
  J Neurooncol 141 (1): 139-149
• 2019, Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Küng M
  Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study [med. app.]
  Pancreatology 19 (1): 64-72
• 2019, de Vocht F
  Analyses of temporal and spatial patterns of glioblastoma multiforme and other brain cancer subtypes in relation to mobile phones using synthetic counterfactuals [epidem.]
  Environ Res 168: 329-335
• 2018, Philips A, Henshaw DL, Lamburn G, O'Carroll MJ
  Authors' Comment on "Brain Tumours: Rise in Glioblastoma Multiforme Incidence in England 1995-2015 Suggests an Adverse Environmental or Lifestyle Factor" [comment]
  J Environ Public Health 2018: 2170208
• 2018, Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R
  Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial [med. app.]
  JAMA Oncol 4 (4): 495-504
• 2018, Anthony P, McArdle S, McHugh M
  Tumor Treating Fields: Adjuvant Treatment for High-grade Gliomas [basics]
  Semin Oncol Nurs 34 (5): 454-464
• 2018, Branter J, Basu S, Smith S
  [details] Tumour treating fields in a combinational therapeutic approach [review]
  Oncotarget 9 (93): 36631-36644
• 2018, Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R, Gambhir SS
  Tumor treating fields increases membrane permeability in glioblastoma cells [med./bio.]
  Cell Death Discov 4: 113
• 2018, Karipidis K, Elwood M, Benke G, Sanagou M, Tjong L, Croft RJ
  Mobile phone use and incidence of brain tumour histological types, grading or anatomical location: a population-based ecological study [epidem.]
  BMJ Open 8 (12): e024489
• 2018, Jo Y, Kim EH, Sai S, Kim JS, Cho JM, Kim H, Baek JH, Kim JY, Hwang SG, Yoon M
  Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy [med./bio.]
  Int J Mol Sci 19 (11): E3684
• 2018, Ouadah NS, Lecomte A, Robidel F, Olsson A, Deltour I, Schüz J, Blazy K, Villégier AS
  Possible effects of radiofrequency electromagnetic fields on in vivo C6 brain tumors in Wistar rats [med./bio.]
  J Neurooncol 140 (3): 539-546
• 2018, Lei KF, Hsieh SC, Goh A, Kuo RL, Tsang NM
  Proliferation arrest, selectivity, and chemosensitivity enhancement of cancer cells treated by a low-intensity alternating electric field [med./bio.]
  Biomed Microdevices 20 (4): 90
• 2018, Shteingauz A, Porat Y, Voloshin T, Schneiderman RS, Munster M, Zeevi E, Kaynan N, Gotlib K, Giladi M, Kirson ED, Weinberg U, Kinzel A, Palti Y
  AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields) [med./bio.]
  Cell Death Dis 9 (11): 1074
• 2018, Mirza FA, Shamim MS
  [details] Tumour Treating Fields (TTFs) for recurrent and newly diagnosed glioblastoma multiforme [review]
  J Pak Med Assoc 68 (10): 1543-1545
• 2018, Straube C, Oechsner M, Kampfer S, Scharl S, Schmidt-Graf F, Wilkens JJ, Combs SE
  Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study [tech./dosim.]
  Radiat Oncol 13: 31
• 2018, Korshoej AR, Hansen FL, Mikic N, von Oettingen G, Sørensen JCH, Thielscher A
  Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations [tech./dosim.]
  PLoS One 13 (8): e0201957
• 2018, Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR
  [details] A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling [review]
  IEEE Rev Biomed Eng 11: 195-207
• 2018, Narvaez CJ, Mall SK, Fountain A, Parr BA, Chittur SV, Kokorin BI, Botsford SF, Startari JF
  Specifically Targeted Electromagnetic Fields Arrest Proliferation of Glioblastoma Multiforme U-87 Cells in Culture [med./bio.]
  Anticancer Res 38 (6): 3255-3266
• 2018, Amiri M, Basiri M, Eskandary H, Akbarnejad Z, Esmaeeli M, Masoumi-Ardakani Y, Ahmadi-Zeidabadi M
  Cytotoxicity of carboplatin on human glioblastoma cells is reduced by the concomitant exposure to an extremely low-frequency electromagnetic field (50 Hz, 70 G) [med./bio.]
  Electromagn Biol Med 37 (3): 138-145